Form 4: Gossamer Bio Director Skye Drynan Receives Stock Options

Director Skye Drynan was granted 115,000 stock options in Gossamer Bio, Inc. as part of the company's non-employee director compensation program.

Summary

• Director Skye Drynan acquired 115,000 stock options in Gossamer Bio, Inc. (GOSS).
• The options have an exercise price of $0.178 per share.
• The grant date for these options is June 4, 2026.
• The options are set to expire on June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.

Negatives

• The issuance of new options results in potential future dilution for existing shareholders.

Risks

• The value of the options is dependent on the future performance of the company's common stock.

Future Outlook

The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while ensuring alignment with long-term corporate performance.

Comparison to Industry Standards

• The grant of stock options as part of a non-employee director compensation program is consistent with standard corporate governance practices for publicly traded biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on the first anniversary of the grant or the next annual meeting of stockholders.

Key Dates

Keywords

Gossamer Bio, GOSS, Form 4, Director Compensation, Stock Options, Insider Transaction